Navigation Links
Risperdal Litigation Scheduled to Convene at September Meeting in Philadelphia Court of Common Pleas, Bernstein Liebhard LLP Reports
Date:8/16/2014

New York, NY (PRWEB) August 16, 2014

A Risperdal (http://www.lawreward.com/risperdal/) meeting is scheduled to take place next month in the Philadelphia Court of Common Pleas, where hundreds of lawsuits over the antipsychotic medication are continuing to move forward, Bernstein Liebhard LLP reports.

According to a Calendar posted on the Court’s website, parties involved in the consolidated Pennsylvania litigation will convene on September 16th at 2:00 p.m. to discuss claims filed against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc. Items likely to be included on the meeting’s agenda will be cases that allege new-onset male breast development caused by the medication, a condition referred to as gynecomastia. Court documents in the proceeding reflect nearly 700 cases involving Risperdal now filed in the Philadelphia Court of Common Pleas, many of which claim the need for a mastectomy, liposuction and other surgical intervention to repair the male breast growth complications was allegedly caused by use of Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is looking forward to the upcoming Risperdal meeting in Philadelphia, as we continue to represent clients who allegedly developed male breast growth complications due to the antipsychotic drug,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm is currently offering free and confidential case evaluations to individuals who may have been injured as a result of the medication.

Risperdal Lawsuits
Risperdal is an atypical antipsychotic medication approved to treat schizophrenia and bipolar disorder in adults and adolescents between the ages of 10 and 17. The drug is also cleared by the U.S. Food and Drug Administration (FDA) to treat irritability in children ages 5-to-16 years old with autistic disorder. According to research, Risperdal is also frequently prescribed off-label for symptoms associated with ADHD.

As Risperdal lawsuits alleging male gynecomastia continue to be filed in the Philadelphia Common Pleas, a report published this month lends evidence to the association between Risperdal and this particular complication. According to a study published on August 6th in the Journal of Clinical Psychopharmacology, 27 out of 174 men exposed to risperidone, the active ingredient in Risperdal, developed male breasts within 60 days. The research was led by scientists from the University of British Columbia and involved health records of more than 82,000 men from 2001 to 2011. The men were aged between 40 and 85 years old.*

According to Risperdal lawsuits filed in the Philadelphia Court of Common Pleas, Johnson & Johnson and Janssen failed to adequately warn men and their doctors about the risk for gynecomastia and other side effects. The companies have also been accused of marketing the drug for off-label uses.

In November 2013, Johnson & Johnson agreed to a $2.5 million settlement with the U.S. Department of Justice involving claims that Risperdal and several other medications were promoted for uses not approved by the FDA. In the case for Risperdal, this may involve promotion of the drug’s marketing in children before it was cleared for pediatric uses in 2006. The federal government also accused Johnson & Johnson and Janssen of withholding information about Risperdal’s side effects, which may include its association with gynecomastia.

Men and young boys who developed gynecomastia after taking Risperdal may be eligible to file a lawsuit seeking compensation for out-of-pocket medical expenses, lost wages, as well as any pain and suffering that may have resulted from use of the medication. Learn more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*journals.lww.com/psychopharmacology/Citation/publishahead/Risperidone_Use_and_Risk_for_Gynecomastia_in_Men_.99394.aspx, Journal of Clinical Psycopharmacology

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.lawreward.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb12099622.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: